Keywords: novartis, fame, study, primary, prevention, elderly, championing
Novartis FAME Study For Primary Prevention In Elderly
Article | 04 November 1998
Novartis is championing the use of its soon-to-be-filedhypercholesterolemia treatment Lescol XL (extended-release 80mg fluvastatin) in a new trial, the Fluvastatin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
